$1.88
1.05% yesterday
Nasdaq, Dec 24, 10:38 pm CET
ISIN
US16385C1045
Symbol
CMMB

Chemomab Therapeutics Ltd - ADR Stock price

$1.88
-0.53 21.99% 1M
-2.92 60.83% 6M
-5.36 74.03% YTD
-4.97 72.56% 1Y
-7.56 80.08% 3Y
-139.56 98.67% 5Y
-689.32 99.73% 10Y
-689.32 99.73% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.02 1.05%
ISIN
US16385C1045
Symbol
CMMB
Industry

Key metrics

Basic
Market capitalization
$11.7m
Enterprise Value
$1.6m
Net debt
positive
Cash
$10.1m
Shares outstanding
492.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
1.0
Financial Health
Equity Ratio
79.8%
Return on Equity
-103.0%
ROCE
-96.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-10.8m | $-12.2m
Net Income
$-10.1m | $-80.4m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
29.7% | 17.5%
Net Income
29.9% | -476.1%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
0.2%
Employees
20
Rev per Employee
$0.0
Show more

Is Chemomab Therapeutics Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Chemomab Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

Buy
88%
Hold
13%

Financial data from Chemomab Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.66 3.66
8% 8%
-
- Research and Development Expense 7.15 7.15
40% 40%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
30% 30%
-
Net Profit -10 -10
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Chemomab Therapeutics Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Chemomab Therapeutics Ltd - ADR Stock News

Neutral
GlobeNewsWire
23 days ago
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory d...
Neutral
GlobeNewsWire
about one month ago
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofite...
Neutral
GlobeNewsWire
about one month ago
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint — —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Present...
More Chemomab Therapeutics Ltd - ADR News

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Head office United States
CEO Adi Mor
Employees 20
Founded 2011
Website www.chemomab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today